Ressources

Bienvenue dans notre banque interrogeable de ressources et de documentation sur l’approvisionnement plus sécuritaire et autres sujets connexes.

 

 

Changing patterns of opioid initiation for pain management in Ontario, Canada: A population-based cross-sectional study

The recent publication of a national guideline and quality standards in Canada have provided clinicians with new, evidence-based recommendations on safe, appropriate opioid use.

Original research | 2022
About prescribers, Clinical guidance, Chronic pain

Optimisation du rôle du pharmacien communautaire auprès des personnes en situation de précarité

Rapport | 2022
à propos des pharmaciens, les guides de pratique clinique, l'hésitation des prescripteurs

Understanding the College’s perspective on safer supply

Commentary | 2022
About prescribers, Policy/Regulatory, Safer supply, Clinical guidance, Hesitancy of prescribers

Collecting data on safer supply prescribing starts with correctly completing the duplicate prescription form

Guidelines | 2022
Clinical guidance, Safer supply, Policy/Regulatory, About prescribers

CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022

Guidelines | 2022
Clinical guidance, About prescribers

Lisdexamfetamine for the treatment of acute methamphetamine withdrawal: A pilot feasibility and safety trial

This study aimed to determine the feasibility and safety of a tapering dose of lisdexamfetamine for the treatment of acute methamphetamine (MA) withdrawal.

Original research | 2022
Stimulants, Withdrawal, Clinical guidance

The impact of benzodiazepine exposure on treatment retention in an open-access methadone program: A retrospective cohort study

We explored whether patients with benzodiazepine exposure at treatment entry would have similar 12-month retention compared to those without benzodiazepine exposure.

Original research | 2022
Substitution/OAT, Clinical guidance

Alleviation of Opioid Withdrawal by Cannabis and Delta-9-Tetrahydrocannabinol: A Systematic Review of Observational and Experimental Human Studies

The therapeutic benefits of cannabinoids remain unclear, especially when weighted against their adverse effects.

Lit review | 2022
Withdrawal, Clinical guidance

Clinical Management of Psychostimulant Withdrawal: Review of the Evidence

This review of clinical research reports the evidence regarding biomedical and behavioral treatments for psychostimulant withdrawal symptoms.

Lit review | 2022
Withdrawal, Stimulants, Clinical guidance

Emergency Department Toolkit for Opioid Use Disorder

Guidelines | 2022
About prescribers, Substitution/OAT, Hospitals, Clinical guidance

Safer Opioid Supply Program Protocols: Parkdale Queen West Community Health Centre, Toronto, Ontario

Guide or handbook | 2022
Clinical guidance, Harm reduction, Policy/Regulatory, Safer supply, About prescribers

Prescribing Characteristics Associated With Opioid Overdose Following Buprenorphine Taper

To understand what prescribing characteristics are associated with opioid overdose following buprenorphine taper.

Original research | 2022
Substitution/OAT, Overdose, Transitions in care/treatment, About PWUD, Clinical guidance

New methadone products: Information for health care providers

Handout | 2022
Clinical guidance, About pharmacists, About prescribers, Substitution/OAT, Transitions in care/treatment

What’s in a name? The ethical implications and opportunities in diagnosing an infant with neonatal abstinence syndrome (NAS)

Commentary | 2022
Withdrawal, About prescribers, Parents/caregivers, Clinical guidance

Recommandations pour la prise en charge de l’infection par le virus de l’hépatite C chez les usagers de drogues par injection

Guide | 2015
les guides de pratique clinique, les services enveloppants

Clinical Management of Opioid Withdrawal

Guidelines | 2022
Withdrawal, Clinical guidance, Harm reduction, About prescribers

Methadone treatment for patients who use fentanyl: Recommendations

Guidelines | 2021
Clinical guidance, Policy/Regulatory, About prescribers, Illegal drugs, Substitution/OAT, Carries/take-home doses

Methadone treatment for patients who use fentanyl: Plain language summary

Guidelines | 2021
Clinical guidance, Policy/Regulatory, About prescribers, Substitution/OAT, Carries/take-home doses, Illegal drugs

Opioid Use Disorder Practice Update

Guidelines | 2022
Clinical guidance, Policy/Regulatory, About prescribers, Harm reduction, Safer supply, Carries/take-home doses, Substitution/OAT

Methadone Take-Home Flexibilities Extension Guidance

Guidelines | 2022
Clinical guidance, Carries/take-home doses, Policy/Regulatory

Affiner votre recherche

Mots clés
Format
Région